Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Antje Schubert"'
Autor:
Antje Schubert
Publikováno v:
Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 140:43-51
Zusammenfassung Hintergrund Veranderungen in Gesellschaft und Gesundheitswesen stellen die Therapiefachberufe Logopadie, Ergotherapie und Physiotherapie vor neue Herausforderungen. Um dem Anspruch des evidenzbasierten Arbeitens nachkommen zu konnen,
Autor:
Christian Thiede, C. Röllig, Christine Borkmann, Claudia D. Baldus, Ulrich Dührsen, Gerhard Ehninger, Marika Mende, Gesine Bug, Lars Fransecky, Matthias Stelljes, Richard Noppeney, Antje Schubert, Johannes Schetelig, Katharina Götze, Dominik Wolf, A.S. Kubasch, Friedrich Stölzel, Malte von Bonin, Mathias Hänel, Hubert Serve, Michael Kramer, Martin Bornhäuser, Alwin Krämer, Regina Herbst, Uta Oelschlägel, Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel, Christoph Groth, Tilmann Bochtler, Anke Mütherig
Publikováno v:
The Lancet Oncology. 19:1668-1679
Summary Background Monitoring of measurable residual disease (MRD) in patients with advanced myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) who achieve a morphological complete remission can predict haematological relapse. In this p
Autor:
Marika Mende, Malte von Bonin, Antje Schubert, Anne Kubasch, Richard Noppeney, Marion Subklewe, Sabine Kayser, Friedrich Stoelzel, Michael Kramer, Gesine Bug, Johannes Schetelig, Gerhard Ehninger, Sebastian Stasik, Schumacher Martin, Christian Thiede, Jan-Henrik Mikesch, Juergen Novotny, Katharina Götze, Mathias Haenel, Anke Mütherig, Alwin Krämer, Dominik Wolf, Regina Herbst, Karsten Spiekermann, Lars Fransecky, Tilmann Bochtler, Uwe Platzbecker, Christoph Röllig, Carsten Müller-Tidow, Jan Moritz Middeke, Katja Sockel, Matthias Stelljes, Hubert Serve, Claudia D. Baldus, Ulrich Duehrsen, Martin Bornhäuser
Publikováno v:
Blood. 136:10-11
Background: Monitoring of measurable residual disease (MRD) in patients (pts) with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who achieve complete remission (CR) can predict hematological relapse. Recently published data
Autor:
Carsten Müller-Tidow, Christoph Röllig, Juergen Novotny, Hubert Serve, Claudia D. Baldus, Karsten Spiekermann, Richard Noppeney, Matthias Stelljes, Uwe Platzbecker, Marika Mende, Ulrich Dührsen, Jan Moritz Middeke, Katja Sockel, Christian Thiede, Schumacher Martin, Katharina Götze, Michael Kramer, Gerhard Ehninger, Mathias Hänel, Anne Sophie Kubasch, Johannes Schetelig, Antje Schubert, Christoph Groth, Lars R. Fransecky, Martin Bornhäuser, Marion Subklewe, Alwin Krämer, Anke Mütherig, Regina Herbst, Tilmann Bochtler, Gesine Bug, Dominik Wolf
Publikováno v:
Blood. 134:644-644
Background: Measurable residual disease (MRD) can identify patients (pts) with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in complete hematological remission (CR) at high risk of relapse even after allogeneic hematopoietic stem ce
Autor:
Antje, Schubert
Publikováno v:
Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen. 140
Today we are faced with changes in society and healthcare needs resulting from demographic transition. Among many other developments, the increasing complexity of healthcare creates new requirements for health professionals. To meet these requirement
Autor:
Michael Wohlgemuth, Marc Bataille, Joachim Ragnitz, Antje Schubert, Claudia Kemfert, Dorothea Schäfer
Publikováno v:
Wirtschaftsdienst. 96:156-158
Publikováno v:
Senologie - Zeitschrift für Mammadiagnostik und -therapie. 13
Publikováno v:
International journal of oncology. 48(6)
S100 calcium binding protein A4 (S100A4) and cysteine-rich angiogenic inducer 61 (CYR61) play important roles in epithelial-mesenchymal-transition (EMT), invasion and metastasis by promoting cancer cell motility. Recently we were able to show that in
Publikováno v:
Breast Cancer Research and Treatment. 130:783-790
Metastasis to bone is a frequent problem of advanced breast cancer. Particularly breast cancers, which do not express estrogen and progesterone receptors and which have no overexpression/amplification of the HER2- neu gene, so called triple-negative
Publikováno v:
Gynecologic Oncology. 119:571-578
Objectives The KiSS-1 gene product is absent or expressed at low level in metastatic breast cancer compared with their nonmetastatic counterparts. A deca-peptide derived from the KiSS-1 gene product, designated kisspeptin-10 (Kp-10), activates a rece